Amneal Pharmaceuticals announced that it has launched its generic version of Exelon Patch, or Rivastigmine Transdermal System, 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. The Company received FDA approval of its Rivastigmine Transdermal System in January 2019, and has received final approval on 10 Abbreviated New Drug Applications this year. According to IQVIA, U.S market annual sales for the 12 months ended January 2019 for Rivastigmine Transdermal System is estimated to be approximately $214M.
https://thefly.com/landingPageNews.php?id=2877800
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.